Daratumumab in Treating Patients With Multiple Myeloma

Completed · Phase 2

Conditions studied: Plasma Cell Myeloma

In brief

This phase II trial studies the side effects and how well daratumumab works in treating patients with multiple myeloma when the infusion is accelerated. Monoclonal antibodies, such as daratumumab, may interfere with the ability of tumor cells to grow and spread.

Key facts

Study ID

NCT02944565

Run by

Ohio State University Comprehensive Cancer Center

People needed

28

Starts

2017-02-22

Expected to finish

2017-07-20

Last updated by the study team

2019-09-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have received >= 2 daratumumab infusions and be scheduled to receive another dose
• All races and ethnic groups are eligible for this study
• Ability to understand and the willingness to sign a written informed consent document

You may not qualify if…

• Any other medical condition, including mental illness or substance abuse, deemed by the principal investigator to likely interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results
• Concurrent use of complementary or alternative medicines that in the opinion of the principal investigator would confound the interpretation of toxicities and/or antitumor activity of the study drug
• Prisoner

Where it is running

• Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.